Molecularly targeted therapies for p53-mutant cancers

作者：Zhao Dekuang; Tahaney William M; Mazumdar Abhijit; Savage Michelle I; Brown Powel H^*

来源：Cellular and Molecular Life Sciences, 2017, 74(22): 4171-4187.

DOI：10.1007/s00018-017-2575-0

• p53 mutation
• Targeted therapies
• Survival pathway
• Gain of function

The tumor suppressor p53 is lost or mutated in approximately half of human cancers. Mutant p53 not only loses its anti-tumor transcriptional activity, but also often acquires oncogenic functions to promote tumor proliferation, invasion, and drug resistance. Traditional strategies have been taken to directly target p53 mutants through identifying small molecular compounds to deplete mutant p53, or to restore its tumor suppressive function. Accumulating evidence suggest that cancer cells with mutated p53 often exhibit specific functional dependencies on secondary genes or pathways to survive, providing alternative targets to indirectly treat p53-mutant cancers. Targeting these genes or pathways, critical for survival in the presence of p53 mutations, holds great promise for cancer treatment. In addition, mutant p53 often exhibits novel gain-of-functions to promote tumor growth and metastasis. Here, we review and discuss strategies targeting mutant p53, with focus on targeting the mutant p53 protein directly, and on the progress of identifying genes and pathways required in p53-mutant cells.

• 出版日期2017-11